

Reference:	FOI.8457.22
Subject:	Diagnosis and treatment of immune thrombocytopenia
Date of Request:	11 March 2022

Requested:

I have some questions about the diagnosis and treatment of immune thrombocytopenia.

1. In the last 6 months, how many patients has your trust treated (for any condition) with the following treatments
 - Avatrombopag
 - Eltrombopag
 - Fostamatinib
 - Romiplostim
2. In the last 6 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3)?
3. In the last 6 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3) ONLY with the following treatments:
 - Avatrombopag
 - Mycophenolate mofetil
 - Rituximab
 - Surgery (splenectomy)
4. Does your trust participate in any clinical trials for the treatment of Immune thrombocytopenia? If so, can you please provide the name of each trial and the number of patients taking part.

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the exact information requested for question 3, as it is estimated that the cost of answering your request would exceed the "appropriate limit" as stated in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. The "appropriate limit" represents the estimated cost of one person spending 18 hours (or 2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with all of the information being requested, the UHB would need to undertake a manual search of all Pharmacy records to distinguish those that have received the treatments provided and cross reference with those diagnosed with Immune Thrombocytopenia, to identify patients treated with the named therapies, during the requested period of September 2021 to February 2022, as this information is not recorded centrally.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under Section 16 of the FoIA, we are required as a public authority, to provide advice and assistance so far as it is reasonable, to individuals who have made a request under FoIA. Therefore, the UHB provides the information it holds for question 3 overleaf.

1. The UHB provides within the table below, the number of patients that have been treated with the medications provided, for all conditions, during the period 1 September 2021 to 28 February 2022.

Medication	Number
Avatrombopag	2
Eltrombopag	35
Fostamatinib	1
Romiplostim	20

2. The UHB confirms that the number of admissions for the treatment of Immune Thrombocytopenia was 255, as recorded for diagnosis code ICD10 on the UHB 's Welsh Patient Administration System (WPAS), during the period 1 July to 31 December 2021.

Please note:- The period taken for the above figures is to capture a full six (6) months' worth of data, as there is a standard clinical coding backlog of up to three (3) months.

3. Under section 16 of the FoIA, the UHB provides, within the table below, the number of patients that have been treated with the named medications, for all conditions, during the period 1 September 2021 to 28 February 2022.

Medication	Number
Avatrombopag	2
Mycophenolate mofetil	46
Rituximab	152
Surgery (splenectomy)	0

4. The UHB confirms that it has no open clinical trials for the treatment of Immune Thrombocytopenia.